WELLESLEY HILLS, Mass., June 1, 2011 /PRNewswire/ -- NMT Medical, Inc. will sell its BioTREK technology platform, which has been assigned to Joseph F. Finn, Jr., C.P.A. ("Finn") of the firm Finn, Warnke & Gayton, LLP to be liquidated for the benefit of NMT Medical creditors, at its sealed bid sale of June 10, 2011.
BioTREK is a technology platform that utilizes a novel bioabsorbable polymer to create a family of percutaneous devices for repair or remodeling of intracardiac defects including patent foramen ovale (PFO), atrial septal defect (ASD) and left atrial appendage (LAA). Unlike other bioabsorbable cardiac implants, BioTREK implants are rendered radiopaque for fluoroscopic visualization using a proprietary technology developed by NMT Medical.
The intellectual property, patents, etc. will be sold at a sealed bid sale on Friday, June 10, 2011 at noon. Persons interested in bidding must sign a Confidentiality Disclosure Agreement ("CDA") obtained from Finn's Office – firstname.lastname@example.org or 781-237-8840. They will then receive a bid package.
About Joseph F. Finn, Jr., C.P.A.
Joseph F. Finn, Jr., C.P.A. is a founding partner of the firm Finn, Warnke & Gayton (www.finnwarnkegayton.com), Certified Public Accountants of Wellesley Hills, Massachusetts. He works primarily in the area of management consulting for distressed enterprises, bankruptcy accounting and related matters, such as assignee for the benefit of creditors and liquidating agent for a corporation. He has been involved in a number of loan workouts and bankruptcy cases for thirty-seven (37) years. His most recent Assignments for the Benefit of Creditors in the biotech field include Spherics, Inc., ActivBiotics, Inc., Prospect Therapeutics, Inc., EPIX Pharmaceuticals, Inc. and Source MDx.
For further information, p
|SOURCE Joseph F. Finn, Jr., C.P.A.|
Copyright©2010 PR Newswire.
All rights reserved